Potensi Patogenik Infeksi Entamoebacoli dengan Komplikasi Syok Sepsis: Sebuah Laporan Kasus Atipikal
DOI:
https://doi.org/10.56951/wv237d49Kata Kunci:
Entamoeba coli, infeksi, sepsis, simtomatik, syokAbstrak
Latar belakang: Entamoeba coli merupakan salah satu protozoa komensal dalam lumen usus manusia yang bersifat nonpatogenik. Hingga saat ini, belum ada laporan kasus infeksi berat terkait Entamoeba coli pada pasien dengan status
gizi dan imunitas baik. Sifat fagositosis alami Entamoeba coli diduga menyebabkan terjadinya kasus infeksi berat dengan komplikasi syok sepsis yang jarang terjadi. Umumnya diagnosis ditegakkan melalui pemeriksaan tinja secara mikroskopis, dengan hasil positif bila ditemukan kista Entamoeba coli. Kasus: Seorang pasien perempuan berusia 65 tahun dengan gejala kolitis, yaitu nyeri perut, mulas disertai diare 4 jam sebelum datang ke IGD, frekuensi diare 6 kali/hari dengan tinja yang cair, kuning kehijauan, dan disertai lendir. Pemeriksaan fisik didapatkan tanda-tanda mengarah ke syok sepsis dengan hasil analisis tinja mikroskopis positif Entamoeba coli. Tata laksana awal berupa pemberian antibiotik spektrum luas dengan tambahan terapi agen amebisidal metronidazole serta tata laksana syok sepsis secara komprehensif memberikan hasil luaran yang baik pada pasien tanpa komplikasi. Kesimpulan: Meskipun dikategorikan sebagai protozoa nonpatogen, kemampuan fagositosis Entamoeba coli dapat memicu respons inflamasi sistemik berat, termasuk sepsis. Diperlukan kewaspadaan klinis yang tinggi terhadap keberadaan Entamoeba coli pada pemeriksaan feses, serta pentingnya diagnosis dini dan penatalaksanaan yang tepat untuk mencegah komplikasi sistemik yang berat.
Unduhan
Referensi
1. Mulinge E, Mbae C, Ngugi B, Irungu T, Matey E, Kariuki S. Entamoeba species infection in patients seeking treatment for diarrhea and abdominal discomfort in Mukuru informal settlement in Nairobi, Kenya. Food Waterborne Parasitol. 2021;23:e00122. doi:10.1016/j.fawpar.2021.e00122.
2. Hamad MNM, Elkhairi ME, Elfaki TM. Entamoeba coli as a potent phagocytic microorganism. Glob J Med Res C Microbiol Pathol. 2017;17(2):1–5. ISSN: 2249-4618.
3. Rattaprasert P, Nitatsukprasert C, Thima K, Chavalitshewinkoon-Petmitr P. Development of nested PCR for identification of Entamoeba coli in human fecal samples. South East Asian Journal Tropical Medicine Public Health. 2022;53(1):21–36.
4. M’Rad S, Chaabane-Banaoues R, Lahmar I, Oumaima H, Mezhoud H, Babba H, et al. Parasitological contamination of vegetables sold in Tunisian retail markets with helminth eggs and protozoan cysts. J Food Prot. 2020;83(7):1104–9. doi:10.4315/JFP-19-559.
5. Afshar MJA, Mehni MB, Rezaeian M, Mohebali M, Baigi V, Amiri S, et al. Prevalence and associated risk factors of human intestinal parasitic infections: A population-based study in the southeast of Kerman province, southeastern Iran. BMC Infect Dis. 2020;20(1):12. doi:10.1186/s12879-019-4730-8.
6. Hotez P. The other intestinal protozoa: Enteric infections caused by Blastocystis hominis, Entamoeba coli, and Dientamoeba fragilis. Semin Pediatr Infect Dis. 2000;11(3):178–81.
7. Inawaty I, Sari IP, Susanto L, Kartikasari DP, Oswari H, Kurniawan A. Occult amebiasis among pediatric with enterocolitis in national referral hospital in Indonesia. Infect Chemother. 2024 Jun 1;56(2):230–8. doi: 10.3947/ic.2023.0099.
8. Jones TPW, Hart JD, Kalua K, Bailey RL. A prevalence survey of enteral parasites in preschool children in the Mangochi District of Malawi. BMC Infect Dis. 2019;19(1):838. doi: 10.1186/s12879-019-4439-8.
9. Shirley DAT, Farr L, Watanabe K, Moonah S. A review of the global burden, new diagnostics, and current therapeutics for amebiasis. Open Forum Infect Dis. 2018;5(7): ofy161. doi:10.1093/ofid/ofy161.
10. Hamad MNM, Elkhairi ME, Elfaki TM. Entamoeba coli infection as a risk factor for cardiovascular disease. European Journal of Biomedical and Pharmaceutical Sciences. 2017;4(10). Available from: www.ejbps.com.
11. Zavala GA, García OP, Camacho M, Ronquillo D, Campos-Ponce M, Doak C, et al. Intestinal parasites: associations with intestinal and systemic inflammation. Parasite Immunol. 2018;40(4):e12518. doi:10.1111/pim.12518.
12. Carrero JC, Reyes-López M, Serrano-Luna J, Shibayama M, Unzueta J, León-Sicairos N, et al. Intestinal amoebiasis: 160 years of its first detection and still remains as a health problem in developing countries. Int J Med Microbiol. 2020;310(1):151358. doi:10.1016/j.ijmm.2019.151358.
13. Dingsdag SA, Hunter N. Metronidazole: an update on metabolism, structure-cytotoxicity and resistance mechanisms. J Antimicrob Chemother. 2018;73(2):265–79. doi: 10.1093/jac/dkx351.
14. Haidar A, De Jesus O. Entamoeba coli infection [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan - [updated 2023 Aug 23; cited 2026 Jan 7]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK564412/figure/article-21138.image.f2/.
15. Shane AL, Mody RK, Crump JA, Tarr PI, Steiner TS, Kotloff K, et al. IDSA 2017 Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin Infect Dis. 2017;65(12):e45–80. doi:10.1093/cid/cix669.
16. Barr W, Smith A. Acute diarrhea in adults. Am Fam Physician. 2014;89(3):180–9.
17. LaRocque R, Harris JB. Approach to the adult with acute diarrhea in resource-abundant settings. UpToDate. Updated May 20, 2025.
18. Garcia LS. Diagnostic Medical Parasitology. 6th ed. Washington DC: ASM Press; 2016.
19. Centers for Disease Control and Prevention (CDC). DPDx – Intestinal (Non-Pathogenic) Amebae [Internet]. Atlanta: CDC; 2025. Available from: https://www.cdc.gov/dpdx.
Unduhan
Terbitan
Bagian
Diterbitkan
Unduhan
Lisensi
Hak Cipta (c) 2026 Christina Saputera

Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.